Home/Filings/4/0001104659-15-013592
4//SEC Filing

NPS PHARMACEUTICALS INC 4

Accession 0001104659-15-013592

CIK 0000890465operating

Filed

Feb 23, 7:00 PM ET

Accepted

Feb 24, 9:18 PM ET

Size

24.2 KB

Accession

0001104659-15-013592

Insider Transaction Report

Form 4
Period: 2015-02-21
GARCEAU ROGER
SVP & CMO
Transactions
  • Disposition to Issuer

    Restricted Stock Units

    2015-02-2110,9050 total
    Common Stock (10,905 underlying)
  • Disposition to Issuer

    Stock Options (right to buy)

    2015-02-2125,9980 total
    Exercise: $3.34Exp: 2020-02-19Common Stock (25,998 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2015-02-217,6650 total
    Common Stock (7,665 underlying)
  • Disposition from Tender

    Common Stock

    2015-02-21$46.00/sh43,349$1,994,0540 total
  • Disposition to Issuer

    Stock Options (right to buy)

    2015-02-2184,9410 total
    Exercise: $8.23Exp: 2023-02-13Common Stock (84,941 underlying)
  • Disposition to Issuer

    Stock Options (right to buy)

    2015-02-2125,1790 total
    Exercise: $8.25Exp: 2021-02-17Common Stock (25,179 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2015-02-2110,5310 total
    Common Stock (10,531 underlying)
  • Disposition to Issuer

    Stock Options (right to buy)

    2015-02-2130,6150 total
    Exercise: $38.27Exp: 2024-02-12Common Stock (30,615 underlying)
  • Disposition to Issuer

    Stock Options (right to buy)

    2015-02-219,9000 total
    Exercise: $8.21Exp: 2022-02-07Common Stock (9,900 underlying)
Footnotes (11)
  • [F1]In connection with the merger of Knight Newco 2, Inc. with and into NPS Pharmaceuticals, Inc. (the "Issuer") on February 21, 2015, each outstanding stock option, whether vested or unvested, was cancelled in exchange for a single lump sum cash payment in an amount equal to the product of (1) the number of shares of the Issuer's common stock subject to such stock option and (2) the execess, if any, of $46.00 over the exercise price per share of such stock option.
  • [F10]On February 17, 2011, the stock options were granted with one fourth vesting on the first anniversary of date of grant and 6.25% vesting every three months thereafter.
  • [F11]On February 19, 2010, the stock options were granted with one fourth vesting on the first anniversary of date of grant and 6.25% vesting every three months thereafter.
  • [F2]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock.
  • [F3]On February 12, 2015, the Restricted Stock Units were granted with (i) one third vesting on the first anniversary of date of grant, (ii) one third on the second anniversary of date of grant and (iii) one third on the third anniversary of date of grant.
  • [F4]In connection with the merger of Knight Newco 2, Inc. with and into the Issuer on February 21, 2015, each outstanding Restricted Stock Unit was cancelled in exchange for a lump sum cash payment in an amount equal to the product of (1) $46.00 and (2) the number of shares of common stock subject to such Restricted Stock Unit.
  • [F5]On February 12, 2014, the Restricted Stock Units were granted with (i) one third vesting on the first anniversary of date of grant, (ii) one third on the second anniverary of date of grant and (iii) one third on the third anniverary of date of grant.
  • [F6]On February 13, 2013, the Restricted Stock Units were granted with (i) one third vesting on the first anniversary of date of grant, (ii) one third on the second anniverary of date of grant and (iii) one third on the third anniverary of date of grant.
  • [F7]On February 12, 2014, the stock options were granted with one fourth vesting on the first anniversary of date of grant and 6.25% vesting every three months thereafter.
  • [F8]On February 13, 2013, the stock options were granted with one fourth vesting on the first anniversary of date of grant and 6.25% vesting every three months thereafter.
  • [F9]On February 7, 2012, the stock options were granted with one fourth vesting on the first anniversary of date of grant and 6.25% vesting every three months thereafter.

Documents

1 file

Issuer

NPS PHARMACEUTICALS INC

CIK 0000890465

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0000890465

Filing Metadata

Form type
4
Filed
Feb 23, 7:00 PM ET
Accepted
Feb 24, 9:18 PM ET
Size
24.2 KB